The Food and Drug Administration (FDA) is taking care of a few approvals and committee meetings ahead of the Thanksgiving holiday week. They include drugs for chronic obstructive pulmonary disease, a pain drug, and a sublingual film formulation of a well-known drug for erectile dysfunction. Here’s a look. Theravance’s Revefenacin for COPD Theravance Biopharma, based in Dublin, … Συνεχίστε να διαβάζετε FDA Action Alert: Theravance’s Approval, Mallinckrodt and Aquestive.
AbbVie staves off 6th Humira biosimilar in US
Angst about Aimovig pickup and reimbursement overshadows Amgen’s solid quarter
FDA Approves Humira Biosimilar That Won’t Be Available Until 2023
Moody's picks 5 early winners in biosimilar market
Mylan – Biocon: Γνωμοδότηση CHMP για το βιο-ομοειδές της πεγκφιλγκραστίμης
5th Humira biosimilar approved in EU as market entry nears
With EpiPen competitors bearing down, can Mylan maintain its lead?
Mylan Strikes $463 Million Deal With Novartis for CF Product Line
Shares of Teva Pharmaceuticals jumped more than 7 percent in afternoon trading Thursday and continue to rise in premarket trading this morning after the U.S. Food and Drug Administration (FDA) approved the company’s generic version of the EpiPen Auto-Injector. This is the first generic version of the widely used EpiPen made by Mylan. The rising consumer cost of the branded EpiPen … Συνεχίστε να διαβάζετε Teva Snags FDA Approval for Generic EpiPen.